What is the most appropriate long‑acting injectable antipsychotic for maintenance treatment of bipolar disorder in an adult who requires reliable adherence?

Best Long-Acting Injectable Antipsychotic for Bipolar Disorder

For maintenance treatment of bipolar disorder requiring reliable adherence, aripiprazole monohydrate LAI is the preferred choice, as it is the only LAI with FDA approval specifically for bipolar I disorder maintenance and demonstrates superior efficacy in preventing manic recurrences with favorable tolerability. 1, 2

Primary Recommendation: Aripiprazole Monohydrate LAI

Aripiprazole monohydrate LAI stands out as the optimal first-line LAI for several critical reasons:

• FDA-approved specifically for bipolar I disorder maintenance (both monthly and bimonthly formulations) 2
• Only partial dopamine D₂ receptor agonist among LAIs, contributing to better tolerability and mood-stabilizing properties 1
• Proven efficacy in preventing manic and mixed episodes in adults with bipolar I disorder 2, 3
• Superior adherence rates compared to first-generation LAIs, particularly with the bimonthly formulation 4
• Well-tolerated profile with injection site pain, sedation, weight increase, and akathisia as most common adverse events 2

Alternative Option: Risperidone LAI

Risperidone LAI serves as a reasonable second-line alternative:

• FDA-approved for bipolar I disorder maintenance as monotherapy or adjunctive to lithium/valproate 5
• Effective in preventing manic symptoms and any mood recurrence compared to placebo 3
• More established track record but with potentially higher metabolic and extrapyramidal side effects compared to aripiprazole 3

Evidence Hierarchy and Strength

The recommendation prioritizes aripiprazole monohydrate LAI based on:

1. Most recent high-quality evidence (2025-2026) demonstrating robust efficacy specifically in bipolar disorder 1, 6, 2
2. Meta-analytic data showing LAIs significantly reduce relapse risk (RR=0.46-0.63) and psychiatric hospitalizations compared to oral antipsychotics 6
3. Real-world effectiveness data confirming higher 12-month adherence with aripiprazole LAI and paliperidone LAI versus first-generation LAIs 4

Critical Limitations to Consider

Depression prevention remains unproven: Neither aripiprazole nor risperidone LAI has demonstrated clear efficacy in preventing depressive recurrences 2, 3. For patients with depression-predominant polarity, oral mood stabilizers (lithium or valproate) should remain the foundation of treatment per WHO guidelines 7.

First-generation depot antipsychotics (haloperidol decanoate) may worsen depressive symptoms and should be avoided in bipolar disorder despite their effectiveness for mania 3.

Practical Implementation Algorithm

Step 1: Confirm bipolar I disorder diagnosis with history of manic episodes requiring reliable adherence

Step 2: Initiate aripiprazole monohydrate LAI:

• Start with monthly formulation (400 mg IM) for first 2 months
• Consider transitioning to bimonthly formulation (960 mg IM every 8 weeks) for enhanced convenience and adherence 2

Step 3: If aripiprazole is contraindicated or not tolerated:

• Switch to risperidone LAI (25-50 mg IM every 2 weeks) 5

Step 4: Maintain concurrent mood stabilizer (lithium or valproate) for at least 2 years after last episode, particularly for depression prevention 7

Step 5: Monitor for:

• Injection site reactions (most common with aripiprazole LAI)
• Metabolic parameters (weight, glucose, lipids)
• Extrapyramidal symptoms (lower risk with aripiprazole vs risperidone)
• Depressive breakthrough (LAIs less effective for depression prevention)

Common Pitfalls to Avoid

1. Using first-generation LAIs as first-line: Haloperidol and zuclopenthixol decanoate have inferior adherence and may worsen depression 3, 4

2. Discontinuing mood stabilizers prematurely: LAIs alone are insufficient for comprehensive bipolar disorder management; maintain lithium or valproate concurrently 7

3. Expecting depression prevention: LAIs primarily prevent manic recurrences; additional strategies needed for depressive episodes 3

4. Overlooking administration interval: Four-week intervals show better adherence than two-week intervals 4

Special Populations

Bipolar II disorder: Evidence is limited; oral mood stabilizers remain preferred 8

Comorbid substance use: Patients with alcohol/substance use develop non-adherence earlier; consider more frequent monitoring 4

Treatment-resistant cases: Paliperidone palmitate may be considered for schizoaffective features, though evidence in pure bipolar disorder is limited 3

The evidence strongly supports aripiprazole monohydrate LAI as the optimal choice when an LAI is indicated for bipolar disorder maintenance, with risperidone LAI as the primary alternative. Both significantly outperform oral antipsychotics in preventing relapse and hospitalization in real-world settings 6.